Condition 1: Vaginal atrophy in postmenopausal women. Condition 2: sexual function of postmenopausal women. Postmenopausal atrophic vaginitis Hypoactive sexual desire disorder
Conditions
Interventions
Intervention 1: Intervention group 1 (Standard treatment group): conjugated estrogen vaginal cream 0.625 mg, one mg for 12 weeks (the first two weeks every night and the next ten weeks twice a week),
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: Women who have had at least one year since their last menstruation or have an FSH test of more than 40 international units Age range 45-65 years old Being sexually active (the participant and his wife) The ultrasound results of the uterus and ovaries are normal Sexual function index score less than 26.5 Having At least two signs of vaginal atrophy through objective evaluation of the vagina Normality of the results of clinical breast examination
Exclusion criteria
Exclusion criteria: People with or suspected of endometrial and breast cancer and undergoing chemotherapy Abnormal bleeding vaginal infection diabetes cardiovascular disease chronic kidney disease active hepatobiliary disease arthritis mental illness People under hormone therapy in the last 12 weeks People treated with non-hormonal drugs for vaginal atrophy during the last 8 weeks A history of unusual severe drug reactions to medicinal plants taking blood pressure drugs vaginal gels and lubricants thiazide diuretics antihistamines antidepressants lithium digoxin psychoactive drugs danazol benzodiazepines barbiturates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective, objective assessment of vaginal atrophy. Timepoint: At the beginning of the research, week 8 and week 12 during treatment, 4 weeks after treatment. Method of measurement: Questionnaire for subjective and objective evaluation of vaginal atrophy and experimental investigation.;Maturation percentage of vaginal cells. Timepoint: Before intervention, after intervention. Method of measurement: Based on Meisel's formula.;Vaginal acidity. Timepoint: Before intervention, after intervention. Method of measurement: PH gauge. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sexual function. Timepoint: At the beginning of the research, week 8 and week 12 during treatment, 4 weeks after treatment. Method of measurement: Female Sexual Function Index-questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahdieh Ghorbani
Ahvaz University of Medical Sciences
Outcome results
None listed